Shandong Buchang Pharmaceuticals Co., Ltd. Class A

Shandong Buchang Pharmaceuticals Co., Ltd. Class A

SSSE:603858
14.79
CNY
-0.18
(-1.20%)
0.12EPS
54.42P/E
15.44BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
8.31
9.99
11.27
11.8
12.03
11.97
12.78
14.47
14.25
13.52
11.98
10.16
11.24
10.9
Basic EPS, GAAP
1.13
1.28
3.42
1.69
1.42
1.65
1.74
1.68
1.05
-1.38
0.29
-0.51
0.34
0.27
Free Cash Flow per Basic Share
0.58
1.52
1.59
0.95
0.44
0.65
1.76
1.29
0.8
2
-0.66
0.69
0.98
- -
Dividend per Share
0.84
1.02
0.13
0.13
1.01
1.04
0.83
2.25
0.67
0.49
1.08
0.25
0.5
0.27
Book Value per Share
3.96
4.26
6.92
10.94
11.41
11.98
11.95
11.99
12.52
11.18
10.5
9.24
9.49
9.81
Tangible Book Value per Share
3.41
3.58
0.21
4.93
5.3
5.86
5.77
5.66
6.27
7.33
7.07
6.43
6.54
6.69
Basic Weighted Avg Shares
1,034
1,034
1,034
1,044
1,152
1,141
1,116
1,106
1,106
1,106
1,106
1,084
1,056
1,048
Sales/Revenue/Turnover
8,592
10,334
11,656
12,321
13,864
13,665
14,255
16,007
15,763
14,951
13,245
11,006
11,875
11,424
Operating Margin (%)
17
16.05
18.38
17.52
12.95
16.93
17.24
15.41
12.47
12.79
9.25
7.43
12.43
13.21
Depreciation Expense
84
100
197
287
296
372
386
425
510
498
593
618
514
- -
Net Income, GAAP
1,169
1,324
3,537
1,769
1,638
1,888
1,946
1,861
1,162
-1,530
319
-554
361
282
Effective Tax Rate (%)
16.15
16.63
9.49
15.9
16.39
15.4
18.7
21.92
30.15
- -
61.51
- -
63.99
72.47
Profit Margin (%)
13.6
12.81
30.34
14.36
11.81
13.82
13.65
11.63
7.37
-10.23
2.41
-5.03
3.04
2.47
Working Capital
1,888
1,261
-976
2,762
1,880
1,676
895
156
1,190
2,030
1,425
435
723
1,705
LT Debt
- -
15
1,261
- -
- -
808
813
851
1,922
2,153
2,109
1,988
2,145
2,455
Total Equity
4,284
4,449
7,260
12,715
13,219
13,927
13,788
13,787
14,323
12,275
11,376
9,808
9,436
9,678
Return on Invested Capital (%)
24.85
22.07
42.39
14.75
10.38
12.04
11.9
10.77
6.34
- -
1.11
- -
1.52
0.95
Return on Capital (%)
21.64
21.63
47.82
17.32
12.27
12.48
12.48
11.79
7.58
- -
3.53
- -
4.32
3.42
Return on Common Equity (%)
29.56
31.14
61.23
17.91
12.72
14.02
14.18
13.62
8.3
-11.48
2.66
-5.07
3.57
2.67

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1,836
1,522
1,224
LT Borrowings
2,533
2,581
2,438
LT Finance Leases
24
21
18
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,055
1,055
1,055
Market Capitalization
17,379
15,397
15,439

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
8,501
8,012
7,936
Cash, Cash Equivalents & STI
1,869
1,644
1,406
Accounts Receivable, Net
617
437
431
Inventories
4,581
4,660
4,614
Total Current Liabilities
6,995
6,690
6,230
Payables & Accruals
- -
- -
- -
ST Debt
1,836
1,522
1,224
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.81%
-7.06%
-3.79%
Free Cash Flow
-8.94%
-36.83%
39.22%
Net Income, GAAP
-87.22%
-165.76%
-165.15%
Sales/Revenue/Turnover
0.63%
-5.42%
7.9%
Total Cash Common Dividend
94.07%
7.83%
94.8%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,641
2,791
3,083
2,491
11,006
2025
2,785
2,879
- -
3,406
11,875
2026
2,579
2,424
3,014
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.1
0.11
0.08
-0.82
-0.51
2025
0.29
0.3
- -
-0.48
0.34
2026
0.3
0.17
0.28
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
0.03
0.16
0.03
0.25
2025
0.03
0.03
- -
0.03
0.5
2026
0.03
0.03
0.19
- -
- -

Company Description

CEO
Chao Zhao
Full Time Employees
7,237
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 369 Zhonghua West Road Heze SD China 274000
IPO Date
Nov 18, 2016
Business
Shandong Buchang Pharmaceuticals Co., Ltd. is engaged in the comprehensive research, development, manufacturing, and distribution of pharmaceutical products within China. The company primarily specializes in Traditional Chinese Medicine (TCM), with a significant focus on medications addressing cardiovascular and cerebrovascular conditions, while also offering treatments for urinary, digestive, respiratory, and gynecological ailments, including diabetes. Established in 1993 and headquartered in Heze, China, the firm markets its diverse portfolio to hospitals, clinics, and pharmacies nationwide. Recently, the company received approvals for expanded production capabilities and new contract manufacturing opportunities, reflecting its ongoing growth and operational enhancements.